Curious about how best to evaluate #CellQuality after #cryopreservation? π₯Ά Our new article explains the principles of cryopreservation, common pitfalls, and best practices for improving post-thaw #CellCounting & #CellViability accuracy.
buff.ly/4V9hS2U
#CellCount #Lab
1
4
24 Oct 2025
We're delighted that the π SpectraSlide has been featured in a β¨ New Technology Spotlight article by @Biocompare! π
π "SpectraSlide AP-1 Simplifies Sample Preparation for Accurate Cell Counting"
ow.ly/LFJ250XeC0r
#CellCount #CellCounting #Lab #LabTech
2
46
16 Oct 2025
ChemoMetec A/S | $CHEMM π©π°π¬π§ͺπ©βπ¬π§¬
On October 14, 2025, UCL, ACBE, UK announced that it had expanded its analytical capabilities with the installation of the ChemoMetec XM40, an automated cell density and viability analyzer.
#cellcounting #lifescience #healthcare #biotech
2
212
12 Oct 2025
ChemoMetec A/S | $CHEMM π©π°π¬π§ͺπ©βπ¬π§¬
$CHEMM combines consumables recurring revenue, sticky workflows, and emerging software optionality. If management executes, the model can evolve into a platform with expanding margins, strong cash flow, & long-term defensibility
#cellcounting
2
167
12 Oct 2025
ChemoMetec A/S | $CHEMM π©π°π¬π§ͺπ©βπ¬π§¬
$CHEMM combines consumables recurring revenue, sticky workflows, and emerging software optionality. If management executes, the model can evolve into a platform with expanding margins, strong cash flow, & long-term defensibility
#cellcounting
9 Oct 2025
Market Update - share buyback
ChemoMetec A/S | $CHEMM
ChemoMetec A/S announces a share repurchase program approved by shareholders in the Annual General Meeting held today - October 09, 2025. Per the approval, the company is authorized to repurchase up to 10% of its own shares.
1
2
344
8 Oct 2025
ChemoMetec A/S | $CHEMM π©π°π¬π§ͺπ©βπ¬π§¬
Quick summary notes β¬οΈ
#lifescience #cellcounting #healthcare #biotech
2
189
5 Oct 2025
$CHEMM π©π°π¬π§ͺπ©βπ¬π§¬
From specialized hardware to a solutions provider, ChemoMetec is strategically evolving its high-margin "razor-and-blade" model to higher-margin software & automation solutions to capture new recurring revenue streams with its XcytoMatic platform
#cellcounting
1
2
202
1 Oct 2025
In life the little things matter. In investing, small caps can too. A small-cap with big numbers.
ChemoMetec A/S | $CHEMM (DKK 10.95B | US$ 1.72B Mkt Cap) π©π°π¬π§ͺπ©βπ¬π§¬
FY25 EBITDA Margin = 52.1%
FY25 EBITDA Growth = 39%
FY25 EV/EBITDA = 40x
#cellcounting #lifescience
28 Sep 2025
ChemoMetec A/S | $CHEMMπ¬π©π°
Your Cheat Sheet for Technology that Counts!
#lifescience #cellcounting #healthcare #biotechπ¬π§ͺπ©βπ¬π§¬
1
2
351
28 Sep 2025
ChemoMetec A/S | $CHEMMπ¬π©π°
Your Cheat Sheet for Technology that Counts!
#lifescience #cellcounting #healthcare #biotechπ¬π§ͺπ©βπ¬π§¬
24 Sep 2025
Cell Counting Market Overview
The #cellcounting market comprises the sale of instruments, consumables, and software used to count and analyze cells for applications ranging from basic biological research to advanced biopharmaceutical manufacturing.
#lifescience #biotech
1
3
509
24 Sep 2025
Cell Counting Market Overview
The #cellcounting market comprises the sale of instruments, consumables, and software used to count and analyze cells for applications ranging from basic biological research to advanced biopharmaceutical manufacturing.
#lifescience #biotech
1
2
147
21 Sep 2025
ChemoMetec A/S | $CHEMMπ¬π©π°
Industry: Healthcare
Sector: Life Sciences Tools & Services
Sub-sector: Cell Counting & Analysis
Forecasts: 10.21% CAGR to reach mkt size ~USD300B by 2030
Overview: $CHEMM is a #lifesciences company specializing in #cellcounting & analysis equipment
1
2
223
21 Sep 2025
ChemoMetec A/S | $CHEMMπ¬π©π°
Industry: Healthcare
Sector: Life Sciences Tools & Services
Sub-sector: Cell Counting & Analysis
Forecasts: 10.21% CAGR to reach mkt size ~USD300B by 2030
Overview: $CHEMM is a #lifesciences company specializing in #cellcounting & analysis equipment
21 Sep 2025
ChemoMetec A/S | $CHEMMπ¬π©π°
Boring until you see:
the 21.02% CAGR returns since IPO
10-Year CAGR
Revenue 19.25%
Op. Profit 31%
FCF 45%
FCFps 43%
10-Year Median Returns
ROIC 29.0%
10-Year Median Margins
Gross Profit 90%
Op. Profit 33%
FCF 27%
#lifescience #cellcounting
1
2
296
21 Sep 2025
ChemoMetec A/S | $CHEMMπ¬π©π°
Boring until you see:
the 21.02% CAGR returns since IPO
10-Year CAGR
Revenue 19.25%
Op. Profit 31%
FCF 45%
FCFps 43%
10-Year Median Returns
ROIC 29.0%
10-Year Median Margins
Gross Profit 90%
Op. Profit 33%
FCF 27%
#lifescience #cellcounting
1
1
6
241
21 Sep 2025
ChemoMetec A/S | $CHEMMπ¬π©π°
Boring until you see:
the 21.02% CAGR returns since IPO
10-Year CAGR
Revenue 19.25%
Op. Profit 31%
FCF 45%
FCFps 43%
10-Year Median Returns
ROIC 29.0%
10-Year Median Margins
Gross Profit 90%
Op. Profit 33%
FCF 27%
#lifescience #cellcounting
20 Sep 2025
$CHEMMπ¬
ChemoMetec CEO Martin Helbo Behrens on Software as an earning stream, a potential new pillar and what potential they see in software - Analysts Q&A. emphasis mine:
1
2
299
17 Sep 2025
Short Thesis
$CHEMM from milk #cellcounting to advanced cell analysis
ChemoMetec A/S is a π©π°#lifescience tools company, which makes cell counters and analysis equipment for pharma, #biotech, academic & research institutions and the food/agricultural sectorπ¬
#healthcare
1/8
1
2
187
13 Sep 2025
$CHEMM long thesis
From milk #cellcounting to advanced cell analysis
ChemoMetec A/S is a π©π°#lifescience tools company, which makes cell counters and analysis equipment for pharma, #biotech, academic & research institutions and the food/agricultural sectorπ¬
#healthcare
1/3
1
1
2
323
11 Sep 2025
ChemoMetec A/S - From milk cell counting to life science applications
$CHEMM 2024/25 Earnings Report π
REV: $495.57M ( 21.7% YoY)
FCF: $177.58M ( 64% YoY)
FCFps: $10.21( 65% YoY)
EPS: $10.71( 37% YoY)
Full Year 2026 Guidance ππ½
#lifesciences #cellcounting #biotech #healthcare
1
3
273
8 Sep 2025
$CHEMM thesis in a nutshell: 4 charts
ChemoMetec A/S is a Danish #lifesciences medical device company specializing in the development, manufacture, and sale of automated cell counters and analysis equipment.
#cellcounting #healthcare #biotech
2
184
3 Sep 2025
$CHEMM stock rose 252% since 2020, while FCF/share compounded 23% annually. The question now is whether future FCF growth can sustain the stock's momentum or if expectations have run ahead of fundamentals. If FCF keeps compounding, the stock could have room
#cellcounting #biotech
1
1
2
193
3 Sep 2025
$CHEMM stock rose 252% since 2020, while FCF/share compounded 23% annually. The question now is whether future FCF growth can sustain the stock's momentum or if expectations have run ahead of fundamentals. If FCF keeps compounding, the stock could have room
#cellcounting #biotech
31 Aug 2025
$CHEMM has grown FCF/share 155% since 2020 (23% CAGR) while diluted shares rose just 3%. With minimal dilution, nearly all growth accrues to shareholders. A classic case of disciplined capital structure enhancing per-share value creation.
#lifesciences #cellcounting #biotech
2
322